

IMPORTANT

IMPORTANT: If you are in any doubt about the contents of this document, you should obtain independent professional advice.

Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(incorporated in the Cayman Islands with limited liability)

[REDACTED]

Number of [REDACTED] under the [REDACTED] : [REDACTED] Shares (subject to adjustment and the [REDACTED])
Number of [REDACTED] : [REDACTED] Shares (subject to adjustment)
Number of [REDACTED] : [REDACTED] Shares (subject to adjustment and the [REDACTED])
Maximum [REDACTED] : HK\$[REDACTED] per [REDACTED] (payable in full on application, plus a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005% and subject to refund) and expected to be not less than HK\$[REDACTED] per [REDACTED]
Nominal value : US\$0.001 per Share
Stock code : [●]

Sole Sponsor



Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager

[REDACTED]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

A copy of this document, having attached thereto the documents specified in the paragraph headed “Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection” in Appendix VI to this document, has been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission of Hong Kong and the Registrar of Companies in Hong Kong take no responsibility as to the contents of this document or any other documents referred to above.

Our Company is incorporated in the Cayman Islands, and a substantial part of our businesses is located in the PRC. Potential investors should be aware of the differences in legal, economic and financial systems between the Cayman Islands, the PRC and Hong Kong and that there are different risk factors relating to the investment in our Company. Potential investors should also be aware that the regulatory frameworks in the Cayman Islands and the PRC are different from the regulatory framework in Hong Kong and should take into consideration the different market nature of our Shares. Such differences and risk factors are set out in the sections headed “Risk Factors” and “Regulation”.

The [REDACTED] is expected to be determined by agreement between our Company and the [REDACTED] (on behalf of the [REDACTED]) on the [REDACTED]. The [REDACTED] is expected to be on or around [REDACTED] or such later time as may be agreed by our Company and the [REDACTED] (on behalf of the [REDACTED]), but in any event no later than [REDACTED].

The [REDACTED] will be not more than HK\$[REDACTED] per [REDACTED] and is currently expected to be not less than HK\$[REDACTED] per [REDACTED] must pay, on application, the maximum [REDACTED] of HK\$[REDACTED] per [REDACTED], unless otherwise announced, together with a brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the [REDACTED] is lower than HK\$[REDACTED]. The Sole Global Coordinator (on behalf of the [REDACTED]), with the consent of our Company, may reduce the number of [REDACTED] being offered under the [REDACTED] and/or the indicative [REDACTED] range stated in this document at any time prior to the morning of the last day for lodging applications under the [REDACTED]. In such a case, a notice of the reduction in the number of [REDACTED] being offered under the [REDACTED] and/or of the [REDACTED] will be published in The Standard (in English) and Hong Kong Economic Times (in Chinese) and on the websites of the Hong Kong Stock Exchange at www.hkexnews.hk and our Company at www.genscript.com not later than the morning of the last day for lodging applications under the [REDACTED]. Further details are set out in the sections headed “Structure of the [REDACTED]” and “[REDACTED]” in this document. If, for any reason, the [REDACTED] is not agreed between our Company and the [REDACTED] (on behalf of the [REDACTED]) on or before [REDACTED], the [REDACTED] will not proceed and will lapse.

Prior to making an investment decision, prospective investors should consider carefully all of the information set out in this document and the related [REDACTED], including the risk factors set out in the section headed “Risk Factors” in this document.

Pursuant to the termination provisions contained in the [REDACTED] in respect of the [REDACTED], the [REDACTED], for themselves and on behalf of the [REDACTED], have the right in certain circumstances, in the sole discretion of the [REDACTED], to terminate the obligations of the [REDACTED] pursuant to the [REDACTED] at any time prior to 8:00 a.m. (Hong Kong time) on the date when dealings in our Shares first commence on The Hong Kong Stock Exchange of Hong Kong Limited (such first dealing date is currently expected to be on [REDACTED]). Further details of the terms of the termination provisions are set out in the paragraph headed “Grounds for termination of the Hong Kong [REDACTED] Agreement” under the section headed “Underwriting” in this document. It is important that you refer to that section for further details.

The [REDACTED] have not been, and will not be, registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered, sold, pledged or transferred within the United States, except that the [REDACTED] may be offered, sold, pledged or transferred to QIBs (i) in reliance on an exemption from registration under the U.S. Securities Act provided by Rule 144A or (ii) in reliance on another exemption from the registration requirements of the U.S. Securities Act. The [REDACTED] may only be offered, sold or delivered outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

* For identification purposes only

[REDACTED]